News from the Office of Research Compliance
- Modifications to the Application for Expedited or Full Committee Review (and the Five Year Application as well)
- What content needs to be included in the protocol for an investigator-initiated study?
- Does your research impact departments other than your own?
- Are you involved in research that is conducted internationally?
- Would you like to schedule an in-person meeting with a member of the ORC Staff?
News from the Food and Drug Administration
- FAQ's and Guidance Document on the FDA Form 1572 (Statement
of Investigators)
News from the Office of Research Compliance
1. Modifications to the Application for Expedited or Full
Committee Review (and the Five Year Application as well)
Section XI.8 (Special Topics: ICH-Good Clinical Practice
Guidelines) (Modified): For our biomedical investigators: In
accordance with AAHRPP recommendations, we are clarifying that
compliance with FDA's ICH-GCP guidance is expected only when the
funding entity (usually Industry, conducting international research)
requires it.You will know if your protocol must comply via specific
reference in the sponsor's protocol and/or in the protocol's
investigator signature page. If your study must be conducted in
compliance with these guidelines, you will need to complete Section
XI.8 of the application. Your responsibilities relating to ICH-GCP
are outlined in Sections 4.1-4.13 of FDA's guidance,
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129515.pdf
As confirmation that you are aware of your responsibilities as an
investigator conducting a study in compliance with ICH-GCP, you will
also need to complete the new Supplemental Form D (available
in the IRBNet Designer Library) and upload it into your IRBNet
package when applying for approval.
Section XI.9 (Special Topics: Does your study involve
investigational devices)(New): In response to comments made by
our AAHRPP site visitors, we needed to gather additional information
to review above and beyond what is captured in the registration
document. Section XI.9 now asks if your study involves the use of
investigational devices, and if it does, you need to provide
information concerning where the device(s) will be stored, the
security of the storage unit/facility, and how the dispensing of the
device(s) will be controlled and documented.
2. What content needs to be included in the protocol for an
investigator-initiated study?
The IRBNet Designer Library now contains a document ('Protocol
Template for Investigator-Initiated Studies') that provides guidance
on sections you should include to ensure a complete study protocol.
3. Does your research impact departments other than your own?
Are you using their facilities or patient populations? Do you list
co-investigators from other departments? If yes to any of those
questions, you must obtain approval from the chairs of those
departments (by sharing your project with them in IRBNet, and
obtaining their e-signature as endorsement). By having all impacted
parties in the know, you will help ensure the smooth conduct of your
study.
4. Are you involved in research that is conducted
internationally?
You might be interested in reviewing the powerpoint presentation
from the March 2010 AAHRPP Webinar on the topic of human subject
protections in transnational (international) sites. It provides an
interesting perspective on providing such protections when faced
with unique challenges, cultural norms, and local laws that factor
into play when dealing with international populations. You can
access the PPT here:
http://www.stonybrook.edu/research/orc/docs/AAHRPP-International-Research-Webinar-Handout.pdf
5. Would you like to schedule an in-person meeting with a member
of the ORC Staff?
We would be happy to accommodate your request. Since our office is
currently undergoing renovation for a period of approximately two
months, please e-mail the staff member with whom you'd like to meet,
or call 631-632-9036 to leave a message, to schedule a convenient
time and place to meet. If you need to drop off paperwork, you
may do so in our temporary location in Melville Library, 5th Floor,
Suite S5421
News from the FDA
The Food and Drug Administration has finalized a 2008 Frequently
Asked Questions guidance document and information sheet related to
FDA Form 1572, "Statement of Investigator." According to one FDA
expert, the guidance contains "significant changes" from the 2008
version, including requiring study coordinators to be listed on the
1572, which means they must file financial disclosure information.
Link to guidance:
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM214282.pdf
Any questions, comments, etc, please feel free to contact me.
Judy Matuk, M.S.
Assistant Vice President
for Research Compliance
Office of Research Compliance
Stony Brook University
Stony Brook, NY 11794-3368
PH: 631-632-9036
FX: 631-632-9839


